Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
LRP16
was previously identified as an estrogen-induced gene in breast cancer cells. The responsiveness of
LRP16
to estrogen and its functional effects in
endometrial cancer
(EC) cells are still unclear. Here, we show that the mRNA level and promoter activity of the
LRP16
gene were significantly increased by 17beta-estradiol (E2) in estrogen receptor alpha (ER alpha)-positive Ishikawa human EC cells. Although the growth rate of Ishikawa cells was not obviously affected by ectopic expression of
LRP16
, the results of a Transwell assay showed an approximate one-third increase of the invasive capacity of
LRP16
-overexpressing cells. As a result of molecular screening, we observed that the expression of E-cadherin, an essential adhesion molecule associated with tumor metastasis, was repressed by
LRP16
. Further promoter analyses demonstrated that
LRP16
inhibited E-cadherin transactivation in a dose-dependent manner. However, the inhibition was abolished by estrogen deprivation, indicating that the downregulation of E-cadherin transcription by
LRP16
requires ER alpha mediation. Chromatin immunoprecipitation analyses revealed that the binding of ER alpha to the E-cadherin promoter was antagonized by
LRP16
, suggesting that
LRP16
could interfere with ER alpha-mediated transcription. These results suggest that the upregulation of
LRP16
by estrogen could be involved in invasive growth by downregulating E-cadherin in human ECs.
...
PMID:Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin. 1789 10